Amikacin
Hematologic Malignancies
Hospital Universitari Vall d'Hebron Research InstituteSmall moleculePhase 4 / ApprovedActive
B
59/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 50/ 100
- Competitive Position
- 73/ 100
Competitive context
50 Active assets in the Hematologic Malignancies cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fludarabine National Cancer Institute (NCI) | Phase 2 | BB |
Evomela Thomas Jefferson University | Phase 2 | BB |
cc-5013 CellCentric Ltd. | Phase 4 | BB |
TACROLIMUS National Cancer Institute (NCI) | Phase 2 | BB |
Monomethyl Fumarate National Cancer Institute (NCI) | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Amikacin is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →